This bill expands New Jersey's definition of "personal data" to explicitly include a person's use of reproductive health care services. It directly affects residents seeking reproductive health care and entities handling their health data, such as providers and pharmacies. The key provision prohibits collecting prescription drug information related to reproductive health services in Prescription Monitoring Programs (PMPs), preventing this sensitive data from being shared with state drug monitoring systems. This change strengthens privacy protections by ensuring such health data cannot be used for purposes unrelated to patient care.
This bill allows New Jersey to expedite the procurement of pharmacy benefits manager (PBM) services, automated reverse auction services, and claims adjudication for the State Health Benefits Program and School Employees’ Health Benefits Program. It requires the Division of Purchase and Property to use a streamlined process - soliciting proposals from qualified vendors without formal advertising and conducting an automated reverse auction to secure competitive pricing. The bill modifies standard procurement rules to shorten timelines, such as limiting the Comptroller’s review to 10 business days and waiving certain advertising requirements. Within 60 days of awarding the contract, the state must report savings and procurement details to the Governor, Legislature, and the public.
This bill requires pharmacy benefits managers (PBMs) operating in New Jersey to annually report detailed financial data to the state Division of Insurance. Specifically, PBMs must disclose minimum/maximum wholesale drug prices, negotiated rebates, volume data, spread pricing revenue, and prior authorization metrics for each drug or drug group. These reports directly affect PBMs and the pharmacies that contract with them, as they increase transparency around drug pricing and rebates. The data will help the state monitor pricing practices and ensure fair reimbursement for pharmacies under insurance plans.
This bill prohibits health insurers, third-party administrators, pharmacy benefits managers, and state health benefit programs (like the State Health Benefits Program and School Employees’ Health Benefits Program) from requiring pre-approval or precertification for covered medical tests, procedures, or prescription drugs. It directly affects patients and healthcare providers by removing insurance company barriers that previously delayed care. The key provision states that payment for covered services must be made without pre-approval if the service is prescribed by a licensed provider and included in the plan. The bill applies to all health and prescription drug plans issued or purchased on or after its effective date. It aims to streamline access to medically necessary treatments by ensuring insurers pay for doctor-recommended care without bureaucratic delays.
This bill, S 2621, establishes the "Equitable Drug Pricing and Patient Access Act" to set minimum reimbursement rates for pharmacies providing prescription drugs to Medicaid beneficiaries in New Jersey. It mandates that pharmacies receive at least the national average drug acquisition cost plus a $10.92 dispensing fee, regardless of whether services are delivered through Medicaid’s fee-for-service or managed care systems. The bill requires Medicaid managed care organizations to include pharmacy choice as a mandatory benefit, ensuring enrollees can select any qualified pharmacy and preventing exclusion of pharmacies based on cost or other criteria. Additionally, it directs the State Auditor to audit pharmacy pricing practices and fund flows within Medicaid to identify potential state savings.
The "Patient and Provider Protection Act" regulates pharmacy benefits managers (PBMs) in New Jersey, directly affecting PBMs, pharmacies (both contracted and independent), and patients who use prescription drugs. It requires PBMs to establish conflict-free committees managing drug formularies, ensures generic drugs are not disadvantaged over higher-cost alternatives, and bans commission-based PBM compensation in favor of flat fees. The bill mandates PBMs to prioritize long-term patient health outcomes, prohibits misleading marketing to steer patients to network pharmacies, and sets reimbursement rules: contracted pharmacies must be paid at least their acquisition cost, while independent pharmacies receive rates no more than 5% below the lowest contracted rate (but not below cost). It also bans contracts conditioning drug rebates on excluding generic drugs and prevents PBMs from restricting independent pharmacies from matching network prices and quantities.
This bill requires health insurance plans in New Jersey to cover prescription drugs for "serious mental illness" (including schizophrenia, bipolar disorder, major depression, and PTSD) without prior authorization or step therapy protocols. It directly affects individuals with these diagnoses who rely on insurance for mental health medications. Key provisions ban insurers from forcing patients to try lower-cost treatments first (step therapy) or requiring pre-approval for covered medications. The bill also mandates insurers to report how they apply medical necessity standards for mental health coverage to ensure parity with physical health benefits. This creates immediate, concrete changes to medication access for covered mental health conditions.
This bill requires pharmacy benefits managers (PBMs) to prioritize the financial interests of patients (covered persons) above those of health insurers. Specifically, PBMs must act as fiduciaries for patients' costs, ensuring they aren't charged more at the pharmacy than the cost-sharing amount or the cash price for the same medication without insurance. The law also prohibits PBMs from requiring patients to pay extra beyond these limits and mandates good-faith dealings with both patients and pharmacies. It applies to all health plans in New Jersey, including state programs and self-insured employer plans.
S 2990 requires New Jersey long-term care facilities to establish specific pharmacy staffing and oversight structures. Each facility must have a consultant pharmacist (who cannot also serve as the pharmacy director or provider and must attest to avoiding conflicts of interest) and either a provider pharmacist or a pharmacy director if the facility has an in-house pharmacy. Facilities must also form a pharmacy committee including the administrator, nursing staff, and consultant pharmacist, which meets at least quarterly and maintains detailed records. Additionally, facilities storing controlled substances must maintain current federal and state drug registration records. The bill codifies existing rules while adding new conflict-of-interest safeguards for pharmacy oversight.
S 464 requires pharmacy benefit managers (PBMs) to pay or deny pharmacy claims within 14 days of receipt, or provide written notice of denial. It mandates PBMs to update pricing information for generic and brand drugs weekly, provide clear access to reimbursement formulas, and establish dispute resolution processes. The bill also grants health plans and the state Department of Banking and Insurance the right to audit PBM records and requires PBMs to disclose conflicts of interest. This directly affects PBMs, pharmacies, and health insurers by increasing transparency and accountability in prescription drug reimbursement.
